Pharmacy Focus : Episode 70

Commentary

Podcast

Pharmacy Focus: Dangers of Drug Diversion for Health Care Professionals

Tom Knight, founder and CEO of Invistics, now part of Wolters Kluwer, discusses the dangers of drug diversion and how this could negatively impact affect patients.

In this week's episode of Pharmacy Focus, Tom Knight, founder and CEO of Invistics, now part of Wolters Kluwer, discusses the dangers of drug diversion and how this could negatively impact affect patients and health care professionals.

Related Videos
Related Content
Sleepless, man suffering from insomnia, sleep apnea or stress. Tired and exhausted guy. Headache or migraine. Awake in the night.
December 20th 2024

FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Varicella zoster or chickenpox virus, ai illustration. A herpes virus which cause chickenpox and shingles - Image credit: Cristina | stock.adobe.com
December 20th 2024

Study: Fatal Disseminated Herpes Zoster in Immunocompetent Individuals

Kennedy Ferruggia, Assistant Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Close up image of skin texture suffering severe urticaria or hives or kaligata on back.
December 20th 2024

Patients With Chronic Idiopathic Urticaria at Higher Risk of Developing Food Allergies

Luke Halpern, Assistant Editor
Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com
December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor